US EditionPublished • loading... • Updated
BioNTech’s ASCO 2025 Oncology Advances: New Data on Bispecific Antibodies, ADCs & mRNA Immunotherapies
Summary by Pharmaphorum
3 Articles
3 Articles
For a long time it was quiet about this once celebrated biotech pearl. After the cometary rise during the pandemic, the phase of disillusionment followed, but now the tide could turn. A new billion deal with a large US partner brings fresh capital, international attention and above all: a clear future perspective.
BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment
BioNTech and Bristol Myers Squibb (BMS) have announced […] The post BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment first appeared on GeneOnline News. The post BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment appeared first on GeneOnline News.
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
